Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma

Cancer Research

Volumn 73, Issue 4, 2013, Pages 1298-1307

  Zhang, Keqiang ^a,b   Chu, Kevin ^a,c   Wu, Xiwei ^a   Gao, Hanlin ^a,b,c   Wang, Jinhui ^a   Yuan, Yate Ching ^a,b   Loera, Sofia ^b   Ho, Kimberley ^a   Wang, Yafan ^a   Chow, Warren ^d   Un, Frank ^a   Chu, Peiguo ^b   Yen, Yun ^a,e  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Departments of Molecular Pathology   (United States)

^c Division of Information Sciences   (United States)

^d Solexa Core Lab   (United States)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CYCLIN DEPENDENT KINASE 4; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR SUBSTRATE 2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN MDM2; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER INHIBITION; CDK4 GENE; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN FU DDLS 1; CELL STRAIN LISA 2; CELL STRAIN SW872; CELL TYPE; COMPARATIVE STUDY; CONTROLLED STUDY; DEDIFFERENTIATED LIPOSARCOMA; FRS2 GENE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOBLAST; LIPOSARCOMA; MDM2 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UNDIFFERENTIATED HIGH GRADE PLEOMORPHIC SARCOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ARGININE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, FIBROBLAST GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84874304239     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2086     Document Type: Article

References (42)

1. Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997;89:693-702. (Pubitemid 27516172)
2. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-29.
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
4. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007;9:R23.
5. Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000; 95:992-8.
6. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64: 1911-4.
7. Emoto N, Isozaki O, Ohmura E, Ito F, Tsushima T, Shizume K, et al. Basic fibroblast growth factor (FGF-2) in renal cell carcinoma, which is indistinguishable from that in normal kidney, is involved in renal cell carcinoma growth. J Urol 1994;152:1626-31. (Pubitemid 24326331)
8. Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T, Cordon-Cardo C. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther 2009;9:1135-44.
9. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003;9:1941-56. (Pubitemid 36687613)
10. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010;16:781-7.
11. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in welldifferentiated and dedifferentiated liposarcoma. Cancer Res 2007; 67:6626-36. (Pubitemid 47105508)
12. Fletcher CD, Mertens F, editors. Tumor of soft tissue and bone. Lyon, France: IARC Press; 2002.
13. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005;65:9226-35. (Pubitemid 41507988)
14. Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011;2011:483154.
15. de Vreeze RS, de Jong D, Nederlof PM, Ariaens A, Tielen IH, Frenken L, et al. Added value of molecular biological analysis in diagnosis and clinical management of liposarcoma: a 30-year single-institution experience. Ann Surg Oncol 2010;17:686-93.
16. Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol 2001;19:3045-50. (Pubitemid 32565442)
17. Massi D, Beltrami G, Capanna R, Franchi A. Histopathological reclassification of extremity pleomorphic soft tissue sarcoma has clinical relevance. Eur J Surg Oncol 2004;30:1131-6.
18. Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M, et al. Functional copy-number alterations in cancer. PLoS One 2008;3: e3179.
19. Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002;62: 2993-8.
20. Erickson-Johnson MR, Seys AR, Roth CW, King AA, Hulshizer RL, Wang X, et al. Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Mod Pathol 2009;22: 1541-7.
21. Ladanyi M, Lewis R, Jhanwar SC, Gerald W, Huvos AG, Healey JH. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 1995;175:211-7.
22. Wang X, Asmann YW, Erickson-Johnson MR, Oliveira JL, Zhang H, Moura RD, et al. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. Genes Chromosomes Cancer 2011;50:849-58.
23. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Fujita C, Ikegami H, et al. Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization. Int J Oncol 2003;22:535-42.
24. Wabitsch M, Bruderlein S, Melzner I, Braun M, Mechtersheimer G, Moller P. LiSa-2, a novel human liposarcoma cell line with a high capacity for terminal adipose differentiation. Int J Cancer 2000;88: 889-94.
25. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 2009;8:713-24.
26. Zhang K,WuJ,WuX,WangX,WangY, Zhou N, et al. p53R2 inhibits the proliferation of human cancer cells in associationwith cell-cycle arrest. Mol Cancer Ther 2011;10:269-78.
27. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4- ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011;54:7066-83.
28. Chung L, Lau SK, Jiang Z, Loera S, Bedel V, Ji J, et al. Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma. Am J Surg Pathol 2009;33: 1594-600.
29. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol 2009;10:R25.
30. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007;23: 657-63. (Pubitemid 46554715)
31. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010;70:4151-62.
32. Zhang Y, Zhang J, Lin Y, Lan Y, Lin C, Xuan JW, et al. Role of epithelial cell fibroblast growth factor receptor substrate 2alpha in prostate development, regeneration and tumorigenesis. Development 2008; 135:775-84. (Pubitemid 351405030)
33. Valencia T, Joseph A, Kachroo N, Darby S, Meakin S, Gnanapragasam VJ. Role and expression of FRS2 and FRS3 in prostate cancer. BMC Cancer 2011;11:484.
34. Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, Coindre JM, et al. HMGA2 is the partner ofMDM2in well-differentiated and dedifferentiated liposarcomas whereasCDK4belongs to a distinct inconsistent amplicon. Int J Cancer 2008;122:2233-41. (Pubitemid 351542325)
35. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007;31:1476-89. (Pubitemid 47482460)
36. Hadari YR, Gotoh N, Kouhara H, Lax I, Schlessinger J. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci U S A 2001;98:8578-83. (Pubitemid 32678070)
37. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagace R, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005;29:1340-7.
38. Gotoh N. Regulation of growth factor signaling by FRS2 family docking/ scaffold adaptor proteins. Cancer Sci 2008;99:1319-25. (Pubitemid 351761719)
39. Zhou W, Feng X, Wu Y, Benge J, Zhang Z, Chen Z. FGF-receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway. Cell Res 2009;19:1165-77.
40. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010;125:105-17.
41. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011;17:5275-86.
42. Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004;23:3501-8.